

UTILIZATION MANAGEMENT MEDICAL POLICY

- POLICY:** Ophthalmology – Vascular Endothelial Growth Factor Inhibitors – Eylea Utilization Management Medical Policy
- Eylea® (aflibercept intravitreal injection – Regeneron)

REVIEW DATE: 11/16/2022; selected revision 02/22/2023

OVERVIEW

Eylea, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the following uses:¹

- **Diabetic macular edema.**
- **Diabetic retinopathy.**
- **Macular edema following retinal vein occlusion.**
- **Neovascular (wet) age-related macular degeneration.**
- **Retinopathy of Prematurity.**

For all of the indications, except retinopathy of prematurity, the recommended dose for Eylea is 2 mg administered by intravitreal injection. Frequency of the dose varies depending on the condition, although all conditions state some patients may need upper limit dosing of once every 4 weeks (approximately every 25 days, monthly). The dose for retinopathy of prematurity is 0.4 mg administered by intravitreal injection; repeat injections may be given and the treatment interval between doses injected into the same eye should be at least 10 days.

Other Uses with Supportive Evidence

Overproduction of VEGF may lead to other eye conditions, including neovascular glaucoma and other retinal and choroidal neovascular conditions affecting the eye.^{2,3} The VEGF inhibitors also have the potential to be used off-label in other eye conditions to prevent or reduce vision loss.^{2,4,5} The use of anti-VEGF agents have been shown to stop the angiogenic process and maintain visual acuity and improve vision in patients with certain neovascular ophthalmic conditions; therefore, research is rapidly evolving on the use of VEGF inhibitors in other neovascular ophthalmic conditions which threaten vision.^{4,5}

POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Eylea. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indications. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Eylea as well as the monitoring required for adverse events and long-term efficacy, approval requires Eylea to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

11/16/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Eylea is recommended in those who meet one of the following criteria:

FDA-Approved Indications

1. **Diabetic Macular Edema.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

Dosing. Approve if the dose meets both of the following criteria (A and B):

- A) The dose is 2 mg administered by intravitreal injection for each eye being treated; AND
- B) The dosing interval is not more frequent than once every 25 days for each eye being treated.

2. **Diabetic Retinopathy.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

Dosing. Approve if the dose meets both of the following criteria (A and B):

- A) The dose is 2 mg administered by intravitreal injection for each eye being treated; AND
- B) The dosing interval is not more frequent than once every 25 days for each eye being treated.

3. **Macular Edema Following Retinal Vein Occlusion.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

Dosing. Approve if the dose meets both of the following criteria (A and B):

- A) The dose is 2 mg administered by intravitreal injection for each eye being treated; AND
- B) The dosing interval is not more frequent than once every 25 days for each eye being treated.

4. **Neovascular (Wet) Age-Related Macular Degeneration.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

Dosing. Approve if the dose meets both of the following criteria (A and B):

- A) The dose is 2 mg administered by intravitreal injection for each eye being treated; AND
- B) The dosing interval is not more frequent than once every 25 days for each eye being treated.

5. **Retinopathy of Prematurity.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

Dosing. Approve if the dose meets both of the following criteria (A and B):

- A) The dose is 0.4 mg administered by intravitreal injection for each eye being treated; AND
- B) The dosing interval is not more frequent than once every 10 days for each eye being treated.

Other Uses with Supportive Evidence

6. **Other Neovascular Diseases of the Eye.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

Note: Examples of other neovascular diseases of the eye include neovascular glaucoma, sickle cell neovascularization, and choroidal neovascular conditions.

Dosing. Approve if the dose meets both of the following criteria (A and B):

- A)** The dose is 2 mg administered by intravitreal injection for each eye being treated; AND
- B)** The dosing interval is not more frequent than once every 25 days for each eye being treated.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Eylea is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Eylea® intravitreal injection [prescribing information]. Tarrytown, NY: Regeneron; February 2023.
2. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. *Expert Opin Investig Drugs*. 2009;18(5):637-646.
3. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol*. 2011;56(2):95-113.
4. Kinnunen K, Ylä-Herttua S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. *Ann Med*. 2012;44(1):1-17.
5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. *Curr Opin Ophthalmol*. 2010;21(2):112-117.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema following Retinal Vein Occlusion, and Neovascular (wet) Age-Related Macular Degeneration: To align with the FDA-approved dosing, the dose was changed from “≤ 2 mg” to “is 2 mg”. Other Neovascular Diseases of the Eye: Examples of other neovascular diseases of the eye were moved to a Note. To align with the FDA-approved dosing, the dose was changed from “≤ 2 mg” to “is 2 mg”.	11/10/2021
Annual Revision	No criteria changes.	11/16/2022
Selected Revision	Retinopathy of Prematurity: This condition was moved to the FDA-Approved Indications; previously, it was included in the Note of examples of Other Neovascular Diseases of the Eye, under “Other Uses with Supportive Evidence”. For this indication, the dosing was changed to be 0.4 mg administered per injection, with the dosing interval changed to be not more frequent than once every 10 days for each eye being treated (previously, it was the same as Other Neovascular Diseases of the Eye, which was 2 mg per treated eye, with a dosing interval of at least 25 days between doses).	02/22/2023